Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 2: GU tumours, non-prostate

LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)


12 Sep 2022


Proffered Paper session 2: GU tumours, non-prostate


Clinical Research

Tumour Site

Urothelial Cancers


Jonathan Rosenberg


Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089


J.E. Rosenberg1, M. Milowsky2, C. Ramamurthy3, N. Mar4, R.R. McKay5, T. Friedlander6, C. Ferrario7, S. Bracarda8, S. George9, H. Moon10, D. Geynisman11, D.P. Petrylak12, D. Borchiellini13, E.F. Burgess14, J.P. Maroto Rey15, A. Carret16, Y. Yu17, M.V. Guseva18, B. Homet Moreno19, P.H. O'Donnell20

Author affiliations

  • 1 Medicine Dept, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Medicine Dept., University of North Carolina - Chapel Hill, 27514 - Chapel Hill/US
  • 3 Hematology - Mays Cancer Center, University of Texas Health Science Center San Antonio, 78245-3207 - San Antonio/US
  • 4 Hematology/oncology, UCI Health - University of California Irvine, 92868 - Orange/US
  • 5 Medical Oncology, UC San Diego, 92037 - La Jolla/US
  • 6 Oncology, UCSF - University of California San Francisco, CA, 94143 - San Francisco/US
  • 7 Oncology, Jewish General Hospital, H3T 1E2 - Montreal/CA
  • 8 Medical & Translational Oncology Unit, Azienda Ospedaliera Santa Maria, 05100 - Terni/IT
  • 9 Medicine Department, Roswell Park Comprehensive Cancer Center, 14263 - Buffalo/US
  • 10 Oncology Department, Kaiser Permanente - Riverside Medical Center, 92505 - Riverside/US
  • 11 Medical Oncology Department, Fox Chase Cancer Center - Main Campus, 19111-2497 - Philadelphia/US
  • 12 Medical Oncology Department, Yale University School of Medicine, 06520 - New Heaven/US
  • 14 Meidcal Oncology Department, Levine Cancer Institute, 28204 - Charlotte/US
  • 15 Department Of Medical Oncology, Hospital de la Santa Creu I Sant Pau, 08041 - Barcelona/ES
  • 16 Clinical Development, Seagen Inc., 98021 - Bothell/US
  • 17 Biostatistics, Seagen Inc., 98021 - Bothell/US
  • 18 Oncology, Global Medica Affairs, Astellas Pharma USA, 60062 - Northbrook/US
  • 19 Clinical Research, Merck & Co., Inc., 07065 - Rahway/US
  • 20 Hematology And Oncology, The University of Chicago, 60637 - Chicago/US


Login to access the resources on OncologyPRO.

Abstract LBA73


There is a critical need for effective and tolerable 1L treatment options in la/mUC. Both EV and P have independently shown an OS benefit in previously treated la/mUC. EV preclinical studies have shown hallmarks of immune cell death potentially augmented by PD-1/PD-L1 inhibitors. Results from a previous cohort formed the rationale for this randomized Cohort K.


Previously untreated cisplatin-ineligible pts with la/mUC were randomized 1:1 to EV (1.25 mg/kg) as monotherapy on Days 1 and 8 or in combination with P (200 mg) on Day 1 of 3-week cycles (EV-103, NCT03288545). The primary endpoint was confirmed objective response rate (ORR) per RECIST v1.1 by BICR. Secondary endpoints included duration of response (DOR) and safety (treatment-related adverse events, TRAEs). There were no formal statistical comparisons between treatment arms.


149 pts were treated: EV+P n=76; EV n=73. Confirmed ORR (95%CI) for EV+P, 64.5% (52.7, 75.1), median DOR was not reached. Confirmed ORR (95%CI) for EV, 45.2% (33.5, 57.3) and median DOR (95%CI) 13.2 mos (6.1, 16.0). TRAEs of special interest included skin reactions (EV+P, n=51 [67.1%]; EV, n=33 [45.2%]), peripheral neuropathy (EV+P, n=46 [60.5%]; EV, n=40 [54.8%]), ocular disorders (eg, dry eye and blurred vision; EV+P, n=20 [26.3%]; EV, n=21 [28.8%]), and hyperglycemia (EV+P, n=11 [14.5%]; EV, n=8 [11.0%]). The majority of treatment-related AESIs were Grade ≤2. Table: 000LBA73

EV+P EV mono
(N=76) (N=73)
Confirmed ORR, % (95% CI) 64.5 (52.7, 75.1) 45.2 (33.5, 57.3)
Best overall response per BICR, %
Complete Response 10.5 4.1
Partial Response 53.9 41.1
Stable Disease 22.4 34.2
Progressive Disease 7.9 9.6
Not Evaluable 3.9 6.8
No Assessment 1.3 4.1
Median (range) time to ORR, mos 2.1 (1.1, 6.6) 2.1 (1.9, 15.4)
Median (range) treatment duration, mos 9.0 (0.6, 26.1+) 5.5 (0.5, 26.9+)
Median (95%CI) follow-up, mos 14.8 (12.9, 17.3) 15.0 (12.7, 17.4)

Data cutoff: June 10, 2022; +Pts remain on treatment.


EV+P showed high ORR with rapid responses and median DOR not reached in a 1L cisplatin-ineligible population. The safety profile was tolerable and generally consistent with the known profile for EV+P. EV monotherapy was consistent with prior experience. These data support ongoing investigations of 1L EV+P in patients with la/mUC who have a high unmet need.

Clinical trial identification


Editorial acknowledgement

Holly Tomlin, MPH, Ray Liao, and Nancy Chang (employees and stockholders, Seagen Inc.) provided writing and editorial assistance.

Legal entity responsible for the study

Seagen Inc., Astellas Pharma, and Merck & Co., Inc.


Seagen Inc., Astellas Pharma, Merck & Co., Inc.


J.E. Rosenberg: Financial Interests, Personal, Advisory Board: Seagen, Astellas, AstraZeneca, EMD-Serono, Mirati, Tyra Biosciences, Alligator Biosciences, Gilead, QED Therapeutics, Boehringer Ingelheim, Genentech, Pfizer, Infinity Pharmaceuticals, BMS, Janssen, Merck, Lilly Oncology, NCCN; Financial Interests, Personal, Invited Speaker: EMD-Serono; Financial Interests, Personal, Invited Speaker, Medical education: Research to Practice, Physicians Education Resource, MJH Associates; Financial Interests, Personal, Invited Speaker, Medical Education: Clinical Care Options; Financial Interests, Personal, Royalties: Wolters Kluyer/Uptodate; Financial Interests, Institutional, Invited Speaker, Coordinating PI of rogaratinib/atezolizumab trial; consultant, trial open at my institution: Bayer; Financial Interests, Personal and Institutional, Invited Speaker, EV-201, EV- 103; consultant, trial open at my institution: Seagen; Financial Interests, Personal and Institutional, Invited Speaker, EV-301, consultant, trial open at my institution: Astellas; Financial Interests, Institutional, Invited Speaker, Consultant, PI of trial, trial open at my institution: AstraZeneca; Financial Interests, Institutional, Invited Speaker, PI of IMVIGOR210 (still open at my institution): Genentech; Financial Interests, Institutional, Invited Speaker, Investigator initiated trial at my institution: QED; Non-Financial Interests, Leadership Role, Bladder Cadre leader for Alliance (NCTN): Alliance for Clinical Trials in Oncology. M. Milowsky: Financial Interests, Personal, Advisory Board: Loxo/Lilly; Financial Interests, Personal, Other, Co-Editor-in-Chief, Clinical Genitourinary Cancer: Elsevier; Financial Interests, Personal, Invited Speaker: Medscape; Financial Interests, Personal, Stocks/Shares: Pfizer, Merck, Gilead Sciences; Financial Interests, Institutional, Invited Speaker: Merck, Roche/Genentech, Bristol-Myers Squibb, Mirati Therapeutics, Incyte, Seagen, G1 Therapeutics, Alliance Foundation Trials, Alliance for Clinical Trials in Oncology, Clovis Oncology, Arvinas, Regeneron. C. Ramamurthy: Financial Interests, Advisory Board: Seagen; Financial Interests, Speaker’s Bureau: Gilead. N. Mar: Financial Interests, Speaker’s Bureau: Seagen, Astellas Pharma. R.R. McKay: Financial Interests, Advisory Board: Janssen, Novartis, Tempus, Exelixis, Pfizer, Bristol-Myers Squibb, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion Therapeutics, Calithera Biosciences, AstraZeneca, Myovant Sciences, Caris Life Sciences, Sorrento Therapeutics; Financial Interests, Funding: Pfizer, Bayer, Tempus. T. Friedlander: Financial Interests, Advisory Board: AbbVie, Dendreon, Dava Oncology, EMD Serono, Merck, Astellas Pharma, Foundation Medicine, Basilea; Financial Interests, Project Lead: Med BioGene; Financial Interests, Other, Travel Expenses: AstrtaZeneca/MedImmune, Genentech/Roche, Jounce Therapeutics; Financial Interests, Other, Honoria: EMD Serono, AstraZeneca/MedImmune, Astellas Scientific and Medical Affairs Inc; Financial Interests, Research Grant: Janssen, Seagen, Incyte, Bristol-Myers Squibb, Neon Therapeutics, Roche/Genetech. C. Ferrario: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Merck, Knights Therapeutics; Financial Interests, Institutional, Invited Speaker: Astellas, AstraZeneca, Lilly, Merck, Novartis, Roche - Genetech, Sanofi, Seattle Genetics, Sermonix, Zymeworks; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Funding: Bayer; Non-Financial Interests, Advisory Role: AstraZeneca, Knights Therapeutics, Merck. S. Bracarda: Financial Interests, Other, Travel Expenses: Astellas Pharma; Financial Interests, Other: Seagen. S. George: Financial Interests, Personal, Advisory Board, advisor/consultant: BMS, Bayer, pfizer, Exelixis, Corvus, Sanofi/ Genzyme, Seattle Genetics, EMD Serono, Eisai, Merck, Aveo, QED therapeutics; Financial Interests, Institutional, Invited Speaker: Pfizer, Merck, Agensys, Novartis, BMS, Bayer, Eisai, Seattle Genetics, Calithera, Corvus, Surface Oncology, Exelixis, Aravive, Aveo, Gilead. H. Moon: Financial Interests, Funding: Bristol-Myers Squibb, Amgen, Prometheus. D. Geynisman: Financial Interests, Personal, Advisory Board: Pfizer, Merck, Exelixis, Astellas, Genentech; Financial Interests, Institutional, Invited Speaker: Genentech, Merck, Harpoon, Seattle Genetics. D.P. Petrylak: Financial Interests, Advisory Role: Bayer, Exelixis, Pfizer, Roche, Astellas Pharma, AstraZeneca, Lilly, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Incyte, Janssen, Pharmacyclics, Seagen, Urogen pharma, Advanced Accelerator Applications, Ipsen, Bicycle Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Regeneron, Gilead Sciences; Financial Interests, Expert Testimony: Celgene, sanofi; Financial Interests, Stocks/Shares: Bellicum Pharmaceuticals, Tyme; Financial Interests, Funding: Progenics, Sanofi, Endocyte, Genentech, Merck, Astellas Medivation, Novartis, AstraZeneca, Bayer, Lilly, Innocrin Pharma, MedImmune, Pfizer, Roche, Seagen, clovis Oncology, Bristol-Meyers Squibb, Advanced Accelerator Applications, Agensys, BioXCel Therapeutics, Eisai, Mirati Therapeutics, Replimune, Medivation, Gilead Sciences. D. Borchiellini: Financial Interests, Advisory Role: Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Ipsen, Janssen-Cilag, MSD Oncology, Pfizer, Sanofi, Merck; Financial Interests, Other, Travel Expenses: Bristol-Myers Squibb, Janssen, Pfizer, Roche; Financial Interests, Funding: Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Exelixis, Infinity Pharmaceuticals, Janssen, MSD, Roche. E.F. Burgess: Financial Interests, Advisory Role: Johnson & Johnson; Financial Interests, Speaker’s Bureau: AstraZeneca, Exelixis; Financial Interests, Stocks/Shares: Exelixis, Becton Dickinson, Calithera Biosciences, Gilead Sciences, Medtronic, Macrogenics, Arvinas, Autolus; Financial Interests, Other, Honoraria: Exelixis, Janssen Oncology, Novartis, Pfizer, Merck; Financial Interests, Funding: Pfizer, Astellas Pharma. J.P. Maroto Rey: Financial Interests, Advisory Role: Astellas, Ipsen, Bristol-Myers Squibb. A. Carret: Financial Interests, Personal, Full or part-time Employment, Senior Medical Director in Clinical Development: Seagen; Financial Interests, Personal, Stocks/Shares, Stocks/Shares/ESPP: Seagen; Non-Financial Interests, Member, ASCO: Seagen; Non-Financial Interests, Member, SIOP: Seagen; Non-Financial Interests, Member, Histiocyte Society: Seagen. Y. Yu: Financial Interests, Stocks/Shares: Seagen; Financial Interests, Full or part-time Employment, Employee: Seagen. M.V. Guseva: Financial Interests, Stocks/Shares: Astellas Pharma. B. Homet Moreno: Financial Interests, Institutional, Full or part-time Employment: Merck Employee; Financial Interests, Institutional, Stocks/Shares: Merck. P.H. O'Donnell: Financial Interests, Stocks/Shares: Allergan; Financial Interests, Other, Honoraria: Genetech/Roche, Merck, Astellas Pharma, Seagen, Atheneum Partners, Health Advances, Janssen, Dedham Group, Pfizer, CLD, Axiom Healthcare Strategies, EMD Serono, IntrinsiQ Specialty Solutions, ISMIE; Financial Interests, Funding: Boehringer Ingelheim, Merck, Genentech/Roche, AstraZeneca/MedImmune, Acerta Pharma, Janssen, Seagen, Bristol-Myers Squibb, Astellas Pharma; Financial Interests, Other, Travel Expenses: Seagen, Astellas, Genentech/Roche; Financial Interests, Other: Janssen, Janssen, Nektar, NIH, Dragonfly Therapeutics, G1 THerapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.